Literature DB >> 30826914

Is Early Reimplantation of the Duodenal-Jejunal Bypass Liner Viable?

Eleni Leventi1,2, Sarah J Günthert1,2, Christine Stier3, Plamen Staikov2,4, Jürgen Stein5,6, Karima Farrag7,8.   

Abstract

The endoscopically implanted duodenal-jejunal bypass liner (DJBL) is an impermeable fluoropolymer device which prevents food making contact with the proximal intestine, thus inducing weight loss and improvement of type 2 diabetes mellitus (T2DM). However, weight and HbA1c levels generally increase post explantation. This study investigated the safety and feasibility of early DJBL reimplantation in five patients with obesity whose glucose levels had relapsed post explantation, examining the effect of reimplantation on weight loss, BMI and T2DM management. All DJBL implantation and explantation procedures were performed without complications. Despite reduction of T2DM medications, reduction in body weight and HbA1c levels resumed after reimplantation. In conclusion, early reimplantation of DJBL appears feasible, safe and effective.

Entities:  

Keywords:  Duodenal–jejunal bypass liner; Glycaemic control; Obesity; Obesity surgery; Type 2 diabetes; Weight loss

Year:  2019        PMID: 30826914     DOI: 10.1007/s11695-019-03758-y

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  9 in total

Review 1.  Obesity.

Authors:  David W Haslam; W Philip T James
Journal:  Lancet       Date:  2005-10-01       Impact factor: 79.321

2.  Is reimplantation of the duodenal-jejunal bypass liner feasible?

Authors:  P Koehestanie; B Betzel; E O Aarts; I M C Janssen; P Wahab; F J Berends
Journal:  Surg Obes Relat Dis       Date:  2015-02-09       Impact factor: 4.734

Review 3.  Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes.

Authors:  Pichamol Jirapinyo; Andrea V Haas; Christopher C Thompson
Journal:  Diabetes Care       Date:  2018-05       Impact factor: 19.112

4.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

5.  Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates.

Authors:  Keith S Gersin; Richard I Rothstein; Raul J Rosenthal; Dimitrios Stefanidis; Stephen E Deal; Timothy S Kuwada; William Laycock; Gina Adrales; Melina Vassiliou; Samuel Szomstein; Stephen Heller; Anne Marie Joyce; Frederick Heiss; Dmitry Nepomnayshy
Journal:  Gastrointest Endosc       Date:  2010-03-20       Impact factor: 9.427

6.  Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss.

Authors:  Harvey J Sugerman; Luke G Wolfe; Domenic A Sica; John N Clore
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

Review 7.  Global burden of obesity in 2005 and projections to 2030.

Authors:  T Kelly; W Yang; C-S Chen; K Reynolds; J He
Journal:  Int J Obes (Lond)       Date:  2008-07-08       Impact factor: 5.095

Review 8.  ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies.

Authors:  Barham K Abu Dayyeh; Nitin Kumar; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Michael Larsen; Shelby Sullivan; Christopher C Thompson; Subhas Banerjee
Journal:  Gastrointest Endosc       Date:  2015-07-29       Impact factor: 9.427

9.  EndoBarrier®: a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes?

Authors:  Nisha Patel; Aruchuna Mohanaruban; Hutan Ashrafian; Carel Le Roux; James Byrne; John Mason; James Hopkins; Jamie Kelly; Julian Teare
Journal:  Obes Surg       Date:  2018-07       Impact factor: 4.129

  9 in total
  1 in total

Review 1.  Bariatric and Metabolic Endoscopy: A New Paradigm.

Authors:  Andrea Telese; Vinay Sehgal; Cormac G Magee; S Naik; S A Alqahtani; L B Lovat; Rehan J Haidry
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.